副教授、碩士研究生導(dǎo)師、乳腺癌預(yù)防治療中心副主任。1998年畢業(yè)于北京醫(yī)科大學(xué)臨床醫(yī)學(xué)專業(yè)。2004年于北京大學(xué)臨床腫瘤學(xué)院獲腫瘤學(xué)博士學(xué)位。2007年赴美國M. D. Anderson腫瘤中心學(xué)習(xí)乳腺整形技術(shù)。主要從事乳腺癌的早期診斷、外科治療和系統(tǒng)性治療等方面的工作和研究。熟練掌握各類乳腺介入診斷技術(shù)和乳腺手術(shù)。在乳腺癌保乳治療、前哨淋巴結(jié)活檢、新輔助/輔助化療、靶向治療和內(nèi)分泌治療等方面積累了豐富的臨床經(jīng)驗(yàn)。于國內(nèi)外醫(yī)學(xué)雜志發(fā)表論文數(shù)篇。

社會(huì)兼職：中國抗癌協(xié)會(huì)乳腺癌專業(yè)委員會(huì)委員，中國醫(yī)藥教育協(xié)會(huì)乳腺癌多學(xué)科診療學(xué)組主任委員，北京癌癥防治學(xué)會(huì)副理事長。曾任中國醫(yī)師協(xié)會(huì)外科醫(yī)師分會(huì)乳腺外科醫(yī)師委員會(huì)常務(wù)委員。

發(fā)表論文

1. Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res. 2005;11:6162-70.

2. 范照青, 歐陽濤, 王天峰, 等.超聲影像引導(dǎo)的乳腺病灶經(jīng)皮穿刺組織病理學(xué)檢查的臨床應(yīng)用. 中華外科雜志，2007,45:1185-7.

3. 范照青，歐陽濤，李金鋒，等。乳腺病變穿刺組織病理學(xué)檢查非惡性結(jié)果的處理。中華醫(yī)學(xué)雜志，2008,88:2387-90.

4. Fan Z, Li J, Wang T, et al. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. Breast. 2013;22:1161-5.

5. Wang X, He Y, Wang T, Xie Y, Li J, Ouyang T, Fan Z. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. Support Care Cancer. 2019 ;27:3019-25.

6. L Wang, Y Li, J Li, T Wang, Y Xie, Y He, Z Fan, T Ouyang. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy. Clin Transl Oncol. 2021 Feb;23(2):240-245. doi: 10.1007/s12094-020-02411-w. Epub 2020 Jun 9.

7. 曹威，何英劍，李金鋒，解云濤，王天峰，范鐵，王歆光，汪星，范照青. 超聲引導(dǎo)下空芯針穿刺活檢診斷的乳腺導(dǎo)管原位癌病理學(xué)低估的危險(xiǎn)因素分析. 中國癌癥雜志. 2020, 30(3): 217-223. doi: 10.19401/j.cnki.1007-3639.2020.03.009

8. 張揚(yáng)，楊飏，王歆光，鐵劍，何英劍，李金鋒，解云濤，王天峰，歐陽濤，范照青. 保乳術(shù)聯(lián)合術(shù)中放療治療早期乳腺癌的近期療效及安全性. 中華腫瘤雜志. 2020,42(8):682-686

9. Lize Wang , Yang Zhang , Yingjian He , Jinfeng Li , Tianfeng Wang , Yuntao Xie, Zhaoqing Fan, Tao Ouyang . Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab. NPJ Breast Cancer. 2021 Jun 11;7(1):75. doi: 10.1038/s41523-021-00284-y.

10. 曹威，何英劍，歐陽濤，李金鋒，解云濤，王天峰，王歆光，汪星，祁萌，范照青. 每周期4.5mg聚乙二醇化重組人粒細(xì)胞集落刺激因子支持乳腺癌劑量密集型化療療效觀察. 中華腫瘤防治雜志. 2021, 28(19):1488-1492. Doi: 10.16073/j.cnki.cjcpt.2021.19.10

11. Xin Wang, Kexin Feng, Wenyan Wang, Xiangzhi Meng, Jiaqi Liu, Yang Yang, Yuting Zhong, Jingruo Li, Shikai Wu, Minghui Li, Pan Ma, Qinfu Feng, Hongmei Zeng, Yuanting Gu, Xiru Li, Zhaoqing Fan, Xiang Wang. Long-term outcomes of intraoperative radiotherapy for early-stage breast cancer in China: a multicenter real-world study. Cancer Commun (Lond). 2022 Mar;42(3):277-280. doi: 10.1002/cac2.12258.

12. Chongshan Gu, Lize Wang, Yingjian He, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Tie Fan, Mi Li, Zhaoqing Fan. Effect of Local Versus General Anesthesia in Breast-Conserving Surgery on Cancer Recurrence and Cost. Cancer Control. Jan-Dec 2022;29:10732748221083078. doi: 10.1177/10732748221083078.